Concepedia

B Ramaswamy

BR

Statistics

Publications

7

Citations

315

H-Index

7

Active since

2009

Affiliations

The Ohio State University(Current)

Fox Chase Cancer Center

City Of Hope National Medical Center

Cornell University

Mayo Clinic in Arizona

B Ramaswamy is an author at The Ohio State University specializing in oncology, medicine, and pharmacology.

Publications per year

2009–2017

7

Publications

7

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

Tanios Bekaii‐Saab, Julie M. Roda, Kristan Guenterberg et al. · Molecular Cancer Therapeutics · 2009 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

B Ramaswamy, Warren Fiskus, Barbara Cohen et al. · Breast Cancer Research and Treatment · 2011 · 87 citations · Full text

Medicine, Oncology, Pharmacology +14

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

NS Kornblum, Judith Manola, Paula Klein et al. · Cancer Research · 2017 · 35 citations

Medicine, Oncology, Pharmacology +17

Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.

Ewa Mrózek, Schaaf Lj, B Ramaswamy et al. · Cancer Research · 2009 · 33 citations

Medicine, Oncology, Pharmacology +17

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(kip1).

Sarmila Majumder, TE Miller, Kalpana Ghoshal et al. · Cancer Research · 2009 · 31 citations · Full text

Medicine, Cancer Biology, Oncology +17

1–5 of 7